21
Oct
2021

Biogen’s Face-plant, an Interchangeable Humira, & Boosters OK’d

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly Buys In Vivo CAR-T, Psychedelics in the Fast Lane, Nektar Surges on Hair Loss Drug
RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund